Search

Introduction: The strategy to Eliminate Yellow Fever Epidemics (EYE) is a global initiative that includes all countries with risk of yellow fever (YF) virus transmission. Of these, 40 countries (27 in Africa and 13 in the Americas) are considered high-risk and targeted for interventions to increase coverage of YF vaccine. Even though the World Health Organization (WHO) recommends that YF vaccine be given concurrently with the first dose of measles-containing vaccine (MCV1) in YF-endemic settings, estimated coverage for MCV1 and YF vaccine have varied widely. The objective of this study was to review global data sources to assess discrepancies in YF vaccine and MCV1 coverage and identify plausible reasons for these discrepancies., Methods: We conducted a desk review of data from 34 countries (22 in Africa, 12 in Latin America), from 2006 to 2016, with national introduction of YF vaccine and listed as high-risk by the EYE strategy. Data reviewed included procured and administered doses, immunization schedules, routine coverage estimates and reported vaccine stock-outs. In the 30 countries included in the comparitive analysis, differences greater than 3 percentage points between YF vaccine and MCV1 coverage were considered meaningful., Results: In America, there were meaningful differences (7-45%) in coverage of the two vaccines in 6 (67%) of the 9 countries. In Africa, there were meaningful differences (4-27%) in coverage of the two vaccines in 9 (43%) of the 21 countries. Nine countries (26%) reported MVC1 stock-outs while sixteen countries (47%) reported YF vaccine stock-outs for three or more years during 2006-2016., Conclusion: In countries reporting significant differences in coverage of the two vaccines, differences may be driven by different target populations and vaccine availability. However,these were not sufficient to completely explain observed differences. Further follow-up is needed to identify possible reasons for differences in coverage rates in several countries where these could not fully be explained., (Published by Elsevier Ltd.)

Home-based records (HBRs) provide an effective, inexpensive mechanism for recording and tracking infant vaccinations, yet stock-outs prevent HBRs from fulfilling their intended function. We describe the annual occurrence of HBR stock-outs during 2014-2016 reported by national immunization programmes to the WHO and UNICEF on the Joint Reporting Form on Immunization. During 2014-16, 48 countries reported at least one HBR stock-out. Thirteen countries reported HBR stock-outs for two of the three years. Forty-four countries reported two or more HBR funding sources in 2016. Challenges persist in ensuring continuous availability of HBRs. HBR stock-outs have important implications as they may impact continuity-of-care, increase inefficiencies at the point-of-care and reduce the ability of caregivers to be effective health advocates. Identifying mechanisms for preventing stock-outs should be a focus of attention for programmes and development partners. Expanded efforts are required to better understand the underlying causes of HBR stock-outs and identify solutions., (Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Introduction: In 2010, the Global Vaccine Action Plan called on all countries to reach and sustain 90% national coverage and 80% coverage in all districts for the third dose of diphtheria-tetanus-pertussis vaccine (DTP3) by 2015 and for all vaccines in national immunization schedules by 2020. The aims of this study are to analyze recent trends in national vaccination coverage in the World Health Organization African Region andto assess how these trends differ by country income category., Methods: We compared national vaccination coverage estimates for DTP3 and the first dose of measles-containing vaccine (MCV) obtained from the World Health Organization (WHO)/United Nations Children's Fund (UNICEF) joint estimates of national immunization coverage for all African Region countries. Using United Nations (UN) population estimates of surviving infants and country income category for the corresponding year, we calculated population-weighted average vaccination coverage by country income category (i.e., low, lower middle, and upper middle-income) for the years 2000, 2005, 2010 and 2015., Results: DTP3 coverage in the African Region increased from 52% in 2000 to 76% in 2015,and MCV1 coverage increased from 53% to 74% during the same period, but with considerable differences among countries. Thirty-six African Region countries were low income in 2000 with an average DTP3 coverage of 50% while 26 were low income in 2015 with an average coverage of 80%. Five countries were lower middle-income in 2000 with an average DTP3 coverage of 84% while 12 were lower middle-income in 2015 with an average coverage of 69%. Five countries were upper middle-income in 2000 with an average DTP3 coverage of 73% and eight were upper middle-income in 2015 with an average coverage of 76%., Conclusion: Disparities in vaccination coverage by country persist in the African Region, with countries that were lower middle-income having the lowest coverage on average in 2015. Monitoring and addressing these disparities is essential for meeting global immunization targets.

In 1974, the World Health Organization (WHO) established the Expanded Program on Immunization* to provide protection against six vaccine-preventable diseases through routine infant immunization (1). Based on 2015 WHO and United Nations Children's Fund (UNICEF) estimates, global coverage with the third dose of diphtheria-tetanus-pertussis vaccine (DTP3), the first dose of measles-containing vaccine (MCV1) and the third dose of polio vaccine (Pol3) has remained stable (84%-86%) since 2010. From 2014 to 2015, estimated global coverage with the second MCV dose (MCV2) increased from 39% to 43% by the end of the second year of life and from 58% to 61% when older age groups were included. Global coverage was higher in 2015 than 2010 for newer or underused vaccines, including rotavirus vaccine, pneumococcal conjugate vaccine (PCV), rubella vaccine, Haemophilus influenzae type b (Hib) vaccine, and 3 doses of hepatitis B (HepB3) vaccine. Coverage estimates varied widely by WHO Region, country, and district; in addition, for the vaccines evaluated (MCV, DTP3, Pol3, HepB3, Hib3), wide disparities were found in coverage by country income classification. Improvements in equity of access are necessary to reach and sustain higher coverage and increase protection from vaccine-preventable diseases for all persons.

The year 2014 marked the 40th anniversary of the World Health Organization’s (WHO) Expanded Program on Immunization, which was established to ensure equitable access to routine immunization services (1). Since 1974, global coverage with the four core vaccines (Bacille Calmette- Guérin vaccine [BCG; for protection against tuberculosis], diphtheria-tetanus-pertussis [DTP] vaccine, poliovirus vaccine, and measles vaccine) has increased from <5% to ≥85%, and additional vaccines have been added to the recommended schedule. Coverage with the 3rd dose of DTP vaccine (DTP3) by age 12 months is an indicator of immunization program performance because it reflects completion of the basic infant immunization schedule; coverage with other vaccines, including the 3rd dose of poliovirus vaccine (polio3); the 1st dose of measles-containing vaccine (MCV1) is also assessed. Estimated global DTP3 coverage has remained at 84%–86% since 2009, with estimated 2014 coverage at 86%. Estimated global coverage for the 2nd routine dose of measles-containing vaccine (MCV2) was 38% by age 24 months and 56% when older age groups were included, similar to levels reported in 2013 (36% and 55%, respectively). To reach and sustain high immunization coverage in all countries, adequate vaccine stock management and additional opportunities for immunization, such as through routine visits in the second year of life, are integral components to strengthening immunization programs and reducing morbidity and mortality from vaccine preventable diseases.

Background: Data on home-based records (HBRs) practices within national immunization programmes are non-existent, making it difficult to determine whether current efforts of immunization programmes related to basic recording of immunization services are appropriately focused., Methods: During January 2014, WHO and the United Nations Children's Fund sent a one-page questionnaire to 195 countries to obtain information on HBRs including type of record used, number of records printed, whether records were provided free-of-charge or required by schools, whether there was a stock-out and the duration of any stock-outs that occurred, as well as the total expenditure for printing HBRs during 2013., Results: A total of 140 countries returned a completed HBR questionnaire. Two countries were excluded from analysis because they did not use a HBR during 2013. HBR types varied across countries (vaccination only cards, 32/138 [23.1%]; vaccination plus growth monitoring records, 31/138 [22.4%]; child health books, 48/138 [34.7%]; combination of these, 27/138 [19.5%] countries). HBRs were provided free-of-charge in 124/138 (89.8%) respondent countries. HBRs were required for school entry in 62/138 (44.9%) countries. Nearly a quarter of countries reported HBR stock-outs during 2013. Computed printing cost per record was

Background: There is currently a re-focus at the global level on the importance of the home-based record within vaccination service delivery as an important information resource but there are few reports of ever and current home-based record prevalence across countries., Methods: We considered all Demographic and Health Surveys (starting with DHS round 3) conducted between 1993 and 2013 for which a final dataset was available in the public domain at the time of the analysis. Ever and current prevalence of home-based records for recording vaccination was estimated for children aged 12-23 months at the time of the survey through a secondary analysis of data from 180 Demographic and Health Surveys conducted in 67 countries derived from questions asked of women aged 15-49 years for their children on home-based record availability and retention. Ever home-based record prevalence is the proportion of children aged 12-23 months who have ever received a home-based record. Current home-based record prevalence is the proportion of children aged 12-23 months for whom a home-based record was available for viewing by the surveyor at the time of the survey., Results: Estimated ever home-based record prevalence was ≥90% in 116 surveys from 52 countries and was <70% in 15 surveys from 7 countries. Estimated current home-based record prevalence was ≥80% in 31 surveys from 23 countries and was <50% in 51 surveys from 24 countries. Current home-based record prevalence was <80% as of the most recent survey during 2010-2013 for five (Bangladesh, Ethiopia, Nigeria, Indonesia and Pakistan) of the ten countries with the largest birth cohorts globally. Among 34 countries that conducted three or more DHS, we observed improvements in both ever and current home-based record prevalence of >10% points in six countries. Current home-based record prevalence increased >10% points in six countries where the ever prevalence was maintained at ≥90% across the period of observation. And, no meaningful change was observed in estimated ever and current home-based record prevalence in 11 countries, five of which maintained ever prevalence ≥90% across the period of observation. High home-based record loss rates were observed in many countries., Conclusions: The results here show that despite improvements in the availability, utilization and retention of home-based records for recording vaccination history in some countries, opportunities remain to change the mind-set in many national immunization programmes around the importance of the home-based record, particularly in countries with large birth cohorts. Immunization programmes are encouraged to monitor ever and current home-based record prevalence. Nationally representative household surveys collecting information on immunization coverage should include ever and current home-based record prevalence in the standard survey reports and tables to better enable programme managers to identify problems and target corrective action., (Copyright © 2015. Published by Elsevier Ltd.)

In 1974, the World Health Organization (WHO) established the Expanded Program on Immunization to ensure that all children have access to routinely recommended vaccines. Since then, global coverage with the four core vaccines (Bacille Calmette-Guérin vaccine [for protection against tuberculosis], diphtheria-tetanus-pertussis vaccine [DTP], polio vaccine, and measles vaccine) has increased from <5% to ≥84%, and additional vaccines have been added to the recommended schedule. Coverage with the third dose of DTP vaccine (DTP3) by age 12 months is a key indicator of immunization program performance. Estimated global DTP3 coverage has remained at 83%-84% since 2009, with estimated 2013 coverage at 84%. Global coverage estimates for the second routine dose of measles-containing vaccine (MCV2) are reported for the first time in 2013; global coverage was 35% by the end of the second year of life and 53% when including older age groups. Improvements in equity of access and use of immunization services will help ensure that all children are protected from vaccine-preventable diseases.

Home-based child vaccination records play an important role in documenting immunization services received by children. We report some of the results of a review of home-based vaccination records from 55 countries. In doing so, we categorize records into three groups (vaccination only cards, vaccination plus cards, child health books) and describe differences in characteristics related to the quality of data recorded on immunization. Moreover, we highlight areas of potential concern and areas in need of further research and investigation to improve our understanding of the home-based vaccination record form related to improved data quality from immunization service delivery., (Copyright © 2014. Published by Elsevier Ltd.)

Background: In November 2009, Sierra Leone conducted a preventive yellow fever (YF) vaccination campaign targeting individuals aged nine months and older in six health districts. The campaign was integrated with a measles follow-up campaign throughout the country targeting children aged 9-59 months. For both campaigns, the operational objective was to reach 95% of the target population. During the campaign, we used clustered lot quality assurance sampling (C-LQAS) to identify areas of low coverage to recommend timely mop-up actions., Methods: We divided the country in 20 non-overlapping lots. Twelve lots were targeted by both vaccinations, while eight only by measles. In each lot, five clusters of ten eligible individuals were selected for each vaccine. The upper threshold (UT) was set at 90% and the lower threshold (LT) at 75%. A lot was rejected for low vaccination coverage if more than 7 unvaccinated individuals (not presenting vaccination card) were found. After the campaign, we plotted the C-LQAS results against the post-campaign coverage estimations to assess if early interventions were successful enough to increase coverage in the lots that were at the level of rejection before the end of the campaign., Results: During the last two days of campaign, based on card-confirmed vaccination status, five lots out of 20 (25.0%) failed for having low measles vaccination coverage and three lots out of 12 (25.0%) for low YF coverage. In one district, estimated post-campaign vaccination coverage for both vaccines was still not significantly above the minimum acceptable level (LT = 75%) even after vaccination mop-up activities., Conclusion: C-LQAS during the vaccination campaign was informative to identify areas requiring mop-up activities to reach the coverage target prior to leaving the region. The only district where mop-up activities seemed to be unsuccessful might have had logistical difficulties that should be further investigated and resolved.

Production of official statistics frequently requires expert judgement to evaluate and reconcile data of unknown and varying quality from multiple and potentially conflicting sources. Moreover, exceptional events may be difficult to incorporate in modelled estimates. Computational logic provides a methodology and tools for incorporating analyst's judgement, integrating multiple data sources and modelling methods, ensuring transparency and replicability, and making documentation computationally accessible. Representations using computational logic can be implemented in a variety of computer-based languages for automated production. Computational logic complements standard mathematical and statistical techniques and extends the flexibility of mathematical and statistical modelling. A basic overview of computational logic is presented and its application to official statistics is illustrated with the WHO & UNICEF estimates of national immunization coverage.

Measles is a highly contagious, vaccine-preventable disease that requires high population immunity in order for transmission to be interrupted. All 6 WHO regions have committed themselves to eliminating measles; however, no region has achieved and sustained elimination. This report describes progress in measles elimination during 2000-2022. Estimated coverage with the first dose of measles-containing vaccine (MCV) worldwide increased from 72% to 86% between 2000 and 2019 and then decreased to 81% in 2021 during the coronavirus disease 2019 (COVID-19) pandemic, the lowest coverage rate since 2008. In 2022, MCV1 coverage increased to 83%. Only 72 (50%) of 144 countries that reported measles cases achieved the measles surveillance indicator target of >2 discarded cases per 100 000 population in 2022. During 2021-2022, estimated measles cases increased by 18%, from 7 802 000 to 9 232 300, and the number of countries experiencing large or disruptive outbreaks increased from 22 to 37. The estimated number of measles deaths increased by 43% during 2021-2022, from 95 000 to 136 200. Nonetheless, an estimated 57 million measles deaths were averted by vaccination during 2000-2022. In 2022, measles vaccination coverage and global surveillance showed some recovery from the setbacks during the COVID-19 pandemic; however, coverage decreased in low-income countries, and, globally, years of suboptimal immunization coverage left millions of children unprotected. Setbacks in coverage during the COVID-19 pandemic must be reversed by renewed efforts to vaccinate all children with 2 MCV doses, strengthen surveillance, prevent outbreaks and accelerate progress towards elimination. La rougeole est une maladie a prevention vaccinale qui est hautement contagieuse et dont la transmission ne peut etre interrompue qu'en presence d'une forte immunite collective. Les 6 Regions de l'OMS se sont toutes engagees a eliminer la rougeole, mais a ce jour, aucune d'entre elles n'a atteint durablement cet objectif. Le present rapport decrit les progres accomplis vers l'elimination de la rougeole au cours de la periode 2000-2022. La couverture mondiale de la vaccination par la premiere dose de vaccin a valence rougeole (MCV) a progresse entre 2000 et 2019, passant de 72% a 86%, mais a ensuite recule pendant la pandemie de COVID-19 pour s'etablir a 81% en 2021, soit le taux le plus faible enregistre depuis 2008. En 2022, la couverture par le MCV1 est remontee a 83%. En 2022, seuls 72 (50%) des 144 pays ayant signale des cas de rougeole ont atteint la cible de l'indicateur de surveillance de la rougeole relatif au nombre de cas ecartes, a savoir >2 cas ecartes pour 100 000 habitants. Dans la periode 2021-2022, le nombre de cas de rougeole signales a augmente de 18%, passant de 7 802 000 a 9 232 300, et, le nombre de pays confrontes a des flambees epidemiques de grande ampleur ou perturbatrices de rougeole est passe de 22 a 37, et le nombre estime de deces dus a la rougeole a augmente de 43%, passant de 95 000 a 136 200. Neanmoins, on estime qu'entre 2000 et 2022, la vaccination a permis d'eviter 57 millions de deces dus a la rougeole. En 2022, on a constate des signes de relevement de la couverture vaccinale et de la surveillance mondiale de la rougeole apres les revers subis lors de la pandemie de COVID-19; la couverture vaccinale a toutefois diminuee dans les pays a faible revenu et, apres des annees de couverture sousoptimale, des millions d'enfants dans le monde restent sans protection contre la maladie. Il est urgent d'inverser le recul de la couverture enregistre pendant la pandemie de COVID-19 en redoublant d'efforts pour vacciner tous les enfants par 2 doses de MCV, renforcer la surveillance, prevenir les flambees epidemiques et accelerer les progres vers l'elimination., Introduction All 6 WHO regions have committed themselves to eliminating measles. (1) The Immunization Agenda 2030 (IA2030) 2 includes measles elimination as a core indicator of impact. IA2030 highlights the [...]

In 2020, the World Health Assembly endorsed the Immunization Agenda 2030 (IA2030), the 2021-2030 global strategy for a world in which everyone, everywhere, at every age fully benefits from vaccines. This report reviews trends in WHO and United Nations Children's Fund (UNICEF) estimates of global, regional and national immunization coverage up to 2022 and documents progress in improving coverage to reduce the number of children who have not received the first dose of a diphtheria-tetanus-pertussis-containing vaccine (DTPcvl) (zero-dose children) worldwide by 50% and to increase coverage with 3 DTPcv doses (DTPcv3). Worldwide, coverage with [greater than or equal to]1 dose DTPcvl increased from 86% in 2021 to 89% in 2022, remaining below the 90% coverage achieved in 2019. Estimated DTPcv3 coverage increased from 81% in 2021 to 84% in 2022 but also remained below the 2019 coverage of 86%. Worldwide in 2022, 14.3 million children were not vaccinated with DTPcv1, a 21% decrease from 18.1 million in 2021 but an 11% increase from 12.9 million in 2019. Most children (84%) who did not receive DTPcv1 in 2022 lived in low- and lower-middle-income countries. Global immunization rates recovered from the reduced levels associated with the coronavirus disease 2019 (COVID-19) pandemic in 2022, but progress was unevenly distributed, especially in low-income countries. Urgent action is needed to provide incompletely vaccinated children with catch-up vaccinations that were missed during the pandemic, restore national vaccination coverage to pre-pandemic levels, strengthen immunization programmes to build resilience to future unforeseen public health events, and further improve coverage to protect children from vaccine-preventable diseases. En 2020, l'Assemblee mondiale de la Sante a approuve le Programme de vaccination a l'horizon 2030 (IA2030), la strategie mondiale 2021-2030 pour un monde oU chaque individu, oU qu'il se trouve et quel que soit son age, beneficie pleinement des vaccins. Ce rapport examine l'evolution des estimations de l'OMS et du Fonds des Nations Unies pour l'enfance (UNICEF) de la couverture vaccinale mondiale, regionale et nationale jusqu'en 2022 et documente les progres accomplis dans l'amelioration de la couverture vaccinale visant a reduire de 50% le nombre d'enfants qui n'ont pas recu la premiere dose du vaccin antidiphterique-antitetanique-anticoquelucheux (DTC1) (enfants dits <>) dans le monde et a augmenter la couverture vaccinale par la troisieme dose de DTC (DTC3). A l'echelle mondiale, la couverture vaccinale par [greater than or equal to]1 dose de DTC a augmente, passant de 86% en 2021 a 89% en 2022, mais reste inferieure a la couverture de 90% atteinte en 2019. La couverture estimee par la DTC3 a egalement augmente, passant de 81% en 2021 a 84% en 2022, mais demeure inferieure a la couverture de 86% en 2019. En 2022, dans le monde, 14,3 millions d'enfants n'ont pas recu la DTC1, un chiffre en baisse de 21% par rapport aux 18,1 millions d'enfants en 2021, mais en augmentation de 11% par rapport aux 12,9 millions d'enfants en 2019. La plupart des enfants (84%) qui n'ont pas recu la DTC1 en 2022 vivaient dans des pays a revenu faible ou intermediaire de la tranche inferieure. Les taux de vaccination ont progresse a l'echelle mondiale, apres un recul associe a la pandemie de maladie a coronavirus 2019 (COVID-19) en 2022, mais de maniere inegale, en particulier dans les pays a faible revenu. Il est urgent d'agir pour rattraper la vaccination des enfants incompletement vaccines parce qu'ils n'ont pas pu etre atteints lors de la pandemie, retablir la couverture vaccinale nationale aux niveaux d'avant la pandemie, renforcer les programmes de vaccination afin d'accroitre la resilience face a de futurs evenements de sante publique imprevus et ameliorer encore la couverture vaccinale pour proteger les enfants contre les maladies evitables par la vaccination., Introduction The Expanded Programme on Immunization was established by WHO in 1974 to ensure that every infant in the world receives vaccines against diphtheria, tetanus, pertussis, poliomyelitis, measles and tuberculosis. [...]

Data from the WHO and UNICEF Estimates of National Immunization Coverage (WUENIC) 2022 revision were analyzed to assess the status of routine immunization in the WHO African Region disrupted by the COVID-19 pandemic. In 2022, coverage for the first and third doses of the diphtheria–tetanus–pertussis-containing vaccine (DTP1 and DTP3, respectively) and the first dose of the measles-containing vaccine (MCV1) in the region was estimated at 80%, 72% and 69%, respectively (all below the 2019 level). Only 13 of the 47 countries (28%) achieved the global target coverage of 90% or above with DTP3 in 2022. From 2019 to 2022, 28.7 million zero-dose children were recorded (19.0% of the target population). Ten countries in the region accounted for 80.3% of all zero-dose children, including the four most populated countries. Reported administrative coverage greater than WUENIC-reported coverage was found in 19 countries, highlighting routine immunization data quality issues. The WHO African Region has not yet recovered from COVID-19 disruptions to routine immunization. It is critical for governments to ensure that processes are in place to prioritize investments for restoring immunization services, catching up on the vaccination of zero-dose and under-vaccinated children and improving data quality. [ABSTRACT FROM AUTHOR]

Pilot testing is crucial when preparing any community-based vaccination coverage survey. In this paper, we use the term pilot test to mean informative work conducted before a survey protocol has been finalized for the purpose of guiding decisions about how the work will be conducted. We summarize findings from seven pilot tests and provide practical guidance for piloting similar studies. We selected these particular pilots because they are excellent models of preliminary efforts that informed the refinement of data collection protocols and instruments. We recommend survey coordinators devote time and budget to identify aspects of the protocol where testing could mitigate project risk and ensure timely assessment yields, credible estimates of vaccination coverage and related indicators. We list specific items that may benefit from pilot work and provide guidance on how to prioritize what to pilot test when resources are limited. [ABSTRACT FROM AUTHOR]

WHO and the United Nations Children&apos;s Fund (UNICEF) annually review data on immunization coverage to estimate national coverage with routine service delivery of the following vaccines: bacille Calmette-Guerin; diphtheria-tetanus-pertussis, first and third doses; either oral polio vaccine or inactivated polio vaccine, third dose of either; hepatitis B, third dose; Haemophilus influenzaetype b, third dose; and a measles virus-containing vaccine, either for measles alone or in the form of a combination vaccine, one dose. The estimates are based on government reports submitted to WHO anal UNICEF anal are supplemented by survey results from the published and grey literature. Local experts, primarily national immunization system managers and WHO/UNICEF regional and national staff, are consulted for additional information on the performance of specific immunization systems. Estimates are derived through a country-by-country review of available data informed and constrained by a set of heuristics; no statistical or mathematical models are used. Draft estimates are made, sent to national authorities for review and comment and modified in light of their feedback. While the final estimates may not differ from reported data, they constitute an independent technical assessment by WHO anal UNICEF of the performance of national immunization systems. These country-specific estimates, available from 1980 onward, are updated annually. L&apos;OMS et le Fonds des Nations Unies pour l&apos;enfance (UNICEF) revisent chaque annee les donnees de couverture vaccinale pour estimer les couvertures des pays par les services de vaccination systematique dans le cas des vaccins suivants : BCG, vaccin antidiphterique-antitetanique-anticoquelucheux, premiere et troisieme doses, vaccin antipoliomyelitique oral ou inactive, troisieme doses, vaccin contre l&apos;hepatite B, troisieme doses, vaccin contre Haemophilus influenzae type b, troisieme dose ; et vaccin a valence rougeole, sous forme de vaccin antirougeoleux uniquement ou de vaccin combine, une dose. Ces estimations reposent sur les rapports soumis par les gouvernements a l&apos;OMS et a l&apos;UNICEF et sont completees par des resultats d&apos;enquetes, tires de la litterature grise ou publiee. Des experts locaux, principalement des gestionnaires de systemes de vaccination nationaux et des membres du personnel regional ou national de l&apos;OMS et de l&apos;UNICEF, sont complementaires consultes pour obtenir des informations sur les performances de certains systemes de vaccination. Les estimations sont obtenues a partir d&apos;une analyse par pays des donnees disponibles, etayee et encadree par un ensemble d&apos;hypotheses heuristiques ; on ne recourt a aucun modele statistique ou mathematique. Des estimations preliminaires sont etablies, envoyees aux autorites nationales pour examen et commentaires et modifiees a la lumiere des observations recues. Bien que les estimations finales puissent ne pas differer des donnees rapportees, elles constituent une evaluation technique independante par l&apos;OMS et l&apos;UNICEF des performances des systemes de vaccination nationaux Ces estimations par pays, disponibles depuis 1980, sont actualisees chaque annee. La OMS y el Fondo de las Naciones Unidas para la Infancia (UNICEF) analizan cada ano los datos sobre la cobertura de vacunacion para calcular la cobertura nacional de los servicios de administracion sistematica de las siguientes vacunas: bacilo de Calmette-Guerin; difteria-tetanos-tos ferina, primera y tercera dosis; vacuna antipoliomielitica oral o inactivada, tercera dosis de cualquiera de eltas; hepatitis B, tercera dosis; Haemophilus influenzae tipo b, tercera dosis; y una vacuna contra el virus dei sarampion, ya sea solo contra esta enfermedad o en forma de vacuna combinada, una dosis. Las estimaciones estan basadas en los informes presentados por los gobiernos a la OMS y el UNICEF, complementados por resultados procedentes de diversas publicaciones y de la literatura gris. Se consulta ademas a expertos locales, principalmente responsables de los sistemas nacionales de inmunizacion y personal regional y nacional de la OMS y el UNICEF, para reunir informacion adicional sobre la eficacia de sistemas de inmunizacion concretos. Las estimaciones se basan en un analisis por paises de los datos disponibles, fundamentado y limitado por un conjunto de reglas empiricas; no se emplean modelos estadisticos ni matematicos. Las estimaciones preliminares son enviadas a las autoridades nacionales para que las examinen y formulen observaciones, y se modifican en funcion de esa retroinformacion. Aunque no siempre distintas de los datos notificados, las estimaciones finales pueden considerarese el resultado de una evaluacion tecnica independiente realizada por la OMS y el UNICEF sobre el desempeno de los sistemas nacionales de inmunizacion. Disponibles desde 1980, estas estimaciones especificas para cada pais son actualizadas cada ano., Introduction WHO recommends that all children receive one dose of bacille Calmette-Guerin vaccine (BCG), three doses of diphtheria--tetanus-pertussis vaccine (DTP), three doses of either oral polio vaccine (OPV) or inactivated [...]

Endorsed by the World Health Assembly in 2020, the Immunization Agenda 2030 strives to reduce morbidity and mortality from vaccine-preventable diseases across the life course (1). This report, which updates previous reports (2), presents global, regional,* and national vaccination coverage estimates and trends as of 2019 and describes the number of surviving infants who did not receive the first dose of diphtheria and tetanus toxoids and pertussis-containing vaccine (DTP1) during the first year of life (i.e., zero-dose children), which serves as a proxy for children with poor access to immunization and other health services. Global estimates of coverage with the third dose of DTP (DTP3), the first dose of measles-containing vaccine (MCV1), and the third dose of polio vaccine (Pol3) ranged from 84% to 86% during 2010-2019. Worldwide, 19.7 million children (15%) were not vaccinated with DTP3 in 2019, 13.8 million (70%) of whom were zero-dose children. During 2010-2019, the number of zero-dose children increased in the African, Americas, and Western Pacific regions. Global coverage with the second MCV dose (MCV2) increased from 42% in 2010 to 71% in 2019. During 2010-2019, global coverage with underused vaccines increased for the completed series of rotavirus vaccine (rota), pneumococcal conjugate vaccine (PCV), rubella-containing vaccine (RCV), Haemophilus influenzae type b vaccine (Hib), hepatitis B vaccine (HepB), and human papillomavirus vaccine (HPV). Achieving universal coverage with all recommended vaccines will require tailored, context-specific strategies to reach communities with substantial proportions of zero-dose and incompletely vaccinated children, particularly those in remote rural, urban poor, and conflict-affected communities (3). [ABSTRACT FROM AUTHOR]

Background: Measles incidence and mortality rates have significantly decreased since vaccine introduction. Despite this progress, however, there has been a global resurgence of measles. To understand the current global epidemiology, we analyzed measles surveillance data.Methods: We analyzed data on measles cases from 2013-2018 reported to the World Health Organization. Univariate analysis was undertaken based on age, vaccination history, onset year, World Health Organization region, and World Bank income status for the country where the case was reported, and a surrogate indicator of the historical strength of the country's immunization program. Annual incidence and a 2013-2018 mean country incidence per million were calculated.Results: From 2013 through 2018, there were 899 800 reported measles cases, of which 57% occurred unvaccinated or undervaccinated persons, with an unknown vaccination history in another 30%. Lower-middle-income countries accounted for 66% of cases, 23% occurred in persons ≥15 years of age. In countries with stronger historical vaccination programs and higher country income, case patients had higher median ages.Conclusions: Although most measles case patients are <15 years of age, an age shift is seen in countries with a higher income or a stronger historical vaccination program. Countries must strengthen immunization programs to achieve high vaccination coverage; some must undertake strategies to reach persons ≥15 years of age and close immunity gaps. [ABSTRACT FROM AUTHOR]

Adopted in 2000, United Nations Millennium Development Goal 4 set a target to reduce child mortality by two thirds by 2015, with measles vaccination coverage as one of the progress indicators. In 2010, the World Health Assembly (WHA) set three milestones for measles control by 2015: 1) increase routine coverage with the first dose of measles-containing vaccine (MCV1) for children aged 1 year to ≥90% nationally and ≥80% in every district; 2) reduce global annual measles incidence to <5 cases per 1 million population; and 3) reduce global measles mortality by 95% from the 2000 estimate (1,2).* In 2012, WHA endorsed the Global Vaccine Action Plan† with the objective to eliminate measles in four World Health Organization (WHO) regions by 2015. Countries in all six WHO regions have adopted measles elimination goals. Measles elimination is the absence of endemic measles transmission in a region or other defined geographical area for ≥12 months in the presence of a well performing surveillance system. This report updates a previous report (3) and describes progress toward global measles control milestones and regional measles elimination goals during 2000-2015. During this period, annual reported measles incidence decreased 75%, from 146 to 36 cases per 1 million persons, and annual estimated measles deaths decreased 79%, from 651,600 to 134,200. However, none of the 2015 milestones or elimination goals were met. Countries and their partners need to act urgently to secure political commitment, raise the visibility of measles, increase vaccination coverage, strengthen surveillance, and mitigate the threat of decreasing resources for immunization once polio eradication is achieved. [ABSTRACT FROM AUTHOR]

Background: Data on home-based records (HBRs) practices within national immunization programmes are nonexistent, making it difficult to determine whether current efforts of immunization programmes related to basic recording of immunization services are appropriately focused. Methods: During January 2014, WHO and the United Nations Children's Fund sent a one-page questionnaire to 195 countries to obtain information on HBRs including type of record used, number of records printed, whether records were provided free-of-charge or required by schools, whether there was a stock-out and the duration of any stock-outs that occurred, as well as the total expenditure for printing HBRs during 2013. Results: A total of 140 countries returned a completed HBR questionnaire. Two countries were excluded from analysis because they did not use a HBR during 2013. HBR types varied across countries (vaccination only cards, 32/138 [23.1%]; vaccination plus growth monitoring records, 31/138 [22.4%]; child health books, 48/138 [34.7%]; combination of these, 27/138 [19.5%] countries). HBRs were provided free-of-charge in 124/138 (89.8%) respondent countries. HBRs were required for school entry in 62/138 (44.9%) countries. Nearly a quarter of countries reported HBR stock-outs during 2013. Computed printing cost per record was

The article discusses a report which described progress made in the global and regional elimination of measles during 2000-2011. There was an increase in the number of countries providing a second dose of measles-containing vaccine (MCV2) through routine services during the period. In 2011, over 225 million children received measles vaccination during 39 supplemental immunization activities (SIA).

Within the overall framework set out in the Global Immunization Vision and Strategy (GIVS) for the period 2006–2015, over 70 countries had developed comprehensive Multi-Year Plans (cMYPs) by 2008, outlining their plans for implementing the GIVS strategies and for attaining the GIVS Goals at the midpoint in 2010 or earlier. These goals are to: (1) reach &geq;90% and &geq;80% vaccination coverage at national and district level, respectively; and (2) reduce measles-related mortality by 90% compared with the 2000 level. Fifty cMYPs were analysed along the four strategic areas of the GIVS: (1) protecting more people in a changing world; (2) introducing new vaccines and technologies; (3) integrating immunization, other health interventions and surveillance in the health system context; and (4) immunizing in the context of global interdependence. By 2010, all 50 countries planned to have introduced hepatitis B (HepB) vaccine, 48 the Haemophilus influenzae type B (Hib) vaccine and only a few countries had firm plans to introduce pneumococcal or rotavirus vaccines. Countries seem to be inadequately prepared in terms of cold-chain requirements to deal with the expected increases in storage that will be required for vaccines, and in making provisions to establish a corresponding surveillance system for planned new vaccine introductions. Immunization contacts are used to deliver other health interventions, especially in the countries in the World Health Organization (WHO) Africa Region. The cost for the planned immunization activities will double to U$27 per infant, of which U$5 per infant is the expected shortfall. Global Alliance for Vaccines and Immunization (GAVI) funding is becoming the largest contributor to immunization programmes. [ABSTRACT FROM PUBLISHER]

Vaccines have made a major contribution to public health, including the eradication of one deadly disease, small pox, and the near eradication of another, poliomyelitis. Through the introduction of new vaccines, such as those against rotavirus and pneumococcal diseases, and with further improvements in coverage, vaccination can significantly contribute to the achievement of the health-related United Nations Millennium Development Goals. The Global Immunization Vision and Strategy (GIVS) was developed by WHO and UNICEF as a framework for strengthening national immunization programmes and protect as many people as possible against more diseases by expanding the reach of immunization, including new vaccines, to every eligible person. This paper briefly reviews global progress and challenges with respect to public vaccination programmes. The most striking recent achievement has been that of reduction of global measles mortality from an estimated 750,000 deaths in 2000 down to 197,000 in 2007. Global vaccination coverage trends continued to be positive. In 2007 most regions reached more than 80% of their target populations with three doses of DPT containing vaccines. However, the coverage remains well short of the 2010 goal on 90% coverage, particularly in the WHO region of Africa (estimated coverage 74%), and South-East Asia, (estimated coverage 69%). Elements that have contributed to the gain in immunization coverage include national multi-year planning, district-level planning and monitoring, re-establishment of outreach services and the establishment of national budget lines for immunization services strengthening. Remaining challenges include the need to: develop and implement strategies for reaching the difficult to reach; support evidence-based decisions to prioritize new vaccines for introduction; strengthening immunization systems to deliver new vaccines; expand vaccination to include older age groups; scale up vaccine preventable disease surveillance; improve quality of immunization coverage monitoring and use the data to improve programme performance; and explore financing options for reaching the GIVS goals, particularly in lower-middle income countries. Although introduction of new vaccines is important, this should not be at the expense of sustaining existing immunization activities. Instead the introduction of new vaccine introduction should be viewed as an opportunity to strengthen immunization systems, increase vaccine coverage and reduce inequities of access to immunization services. [ABSTRACT FROM AUTHOR]

Highlights • All countries were asked how they conducted measles, rubella, and congenital rubella syndrome surveillance. • 86% of countries reported conducting measles surveillance in line with global recommendations. • 77% of countries reported conducting rubella surveillance in line with global recommendations. • 77% of countries report conducting congenital rubella syndrome surveillance. Abstract Background All six World Health Organization (WHO) regions have committed to eliminate measles, and three WHO regions have committed to eliminate rubella. One of the key tenets of measles and rubella elimination is to have a strong surveillance system in place. The presence of a case-based measles and rubella surveillance system that is national, population-based, provides laboratory confirmation, and directs action, is one of the requirements for elimination-standard surveillance. Methods In order to understand the global landscape for measles and rubella surveillance, a questionnaire was sent to all 194 WHO member states (herein referred to as countries) requesting information on how surveillance was conducted for measles, rubella, and congenital rubella syndrome. Data were supplemented with information provided to WHO through other reporting mechanisms and by national policy documents available to the public. Frequencies and percentages were calculated. Results Data were available to review from 164 (85%) countries, although not every country responded to every question. Case-based, population-based, national surveillance with laboratory confirmation was reported to be conducted in 136 (86%) of 158 countries for measles and 122 (77%) of 158 countries for rubella. Congenital rubella syndrome surveillance was reported to be conducted by 126 (77%) of 163 countries. Gaps were noted in the quality of measles-rubella surveillance conducted, and 26 (16%) of 158 countries reported not including all healthcare providers as mandatory reporters. Conclusions Many countries reported having some of the essential components in place to conduct elimination-standard surveillance for measles and rubella; however, in order to achieve elimination, the quality of surveillance needs to improve to detect all cases. In those countries without these essential components of elimination-standard surveillance, the first step is to implement these components. [ABSTRACT FROM AUTHOR]

Household surveys are frequently used as means of vaccination coverage measurement, but obtaining accurate survey estimates present several challenges. In 2015, the World Health Organization (WHO) released a working draft of its updated Vaccination Coverage Survey Reference Manual that moved well beyond the traditional Expanded Program on Immunization (EPI) survey design. In April 2017, WHO convened a four-day meeting, to review lessons learned using the updated manual and to define an agenda for operational research about vaccination coverage surveys. About 70 stakeholders, including EPI managers and participants from 10 countries that have used the updated Survey Manual, survey experts, statisticians, partners, representatives from WHO regional offices and headquarters, and providers of technical assistance discussed methodological issues from sampling to accurately ascertaining a person’s vaccination status, optimizing data collection and data management and conducting appropriate analyses. Participants also discussed data sharing and how to best survey data for immunization decision-making. The lessons learned from the use of the updated WHO Survey Manual related mainly to operational issues to implement better quality vaccination coverage surveys. It resulted in a list of 23 recommendations for WHO, donors and partners, immunization programs, and household surveys that collect immunization data. Similarly, 14 research topics, categorized in six themes (overall survey conduction, sampling, vaccination ascertainment, data collection, data analysis and use, and inclusion of questions on knowledge, attitudes and practices) were prioritized. Top areas of further work included improving our understanding of the accuracy of caregiver recall when documented evidence of vaccination is not available, improving engagement and coordination between immunization programs and entities conducting multi-purpose household surveys such as Demographic and Health Survey and Multiple Cluster Indicator Survey, improving mechanisms for sharing vaccination survey datasets and documentation, and making better use of survey results to translate data into knowledge for decision-making. This manuscript summarizes the meeting proceedings and provides an update of actions taken by WHO since this meeting. [ABSTRACT FROM AUTHOR]

WHO/UNICEF estimates for HPV vaccination coverage from 2010 to 2019 are analyzed against the backdrop of the 90% coverage target for HPV vaccination by 2030 set in the recently approved global strategy for cervical cancer elimination as a public health problem. As of June 2020, 107 (55%) of the 194 WHO Member States have introduced HPV vaccination. The Americas and Europe are by far the WHO regions with the most introductions, 85% and 77% of their countries having already introduced respectively. A record number of introductions was observed in 2019, most of which in low- and middle- income countries (LMIC) where access has been limited. Programs had an average performance coverage of around 67% for the first dose and 53% for the final dose of HPV. LMICs performed on average better than high- income countries for the first dose, but worse for the last dose due to higher dropout. Only 5 (6%) countries achieved coverages with the final dose of more than 90%, 22 countries (21%) achieved coverages of 75% or higher while 35 (40%) had a final dose coverage of 50% or less. When expressed as world population coverage (i.e., weighted by population size), global coverage of the final HPV dose for 2019 is estimated at 15%. There is a long way to go to meet the 2030 elimination target of 90%. In the post-COVID era attention should be paid to maintain the pace of introductions, specially ensuring the most populous countries introduce, and further improving program performance globally. [ABSTRACT FROM AUTHOR]